key: cord-0295259-2afslx7p authors: Wang, K.; Cao, Y. R.; Zhou, Y.; Wu, J.; Jia, Z.; Hu, Y.; Yisimayi, A.; Fu, W.; Wang, L.; Liu, P.; Fan, K.; Chen, R.; Jing, L.; Wang, Y.; Ge, X.; Zhang, Q.; Wang, N.; Wu, W.; Gao, Y.; Miao, J.; Jiang, Y.; Qin, L.; Zhu, L.; Huang, W.; Zhang, Y.; Zhang, H.; Li, B.; Gao, Q.; Xie, X. S.; Wang, Q.; Wang, X. title: A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2 date: 2021-09-05 journal: nan DOI: 10.1101/2021.09.02.21261735 sha: 47f40e5be731eda8ad0084242f992b39bf54f7fe doc_id: 295259 cord_uid: 2afslx7p Emergence of variants of concern (VOC) with altered antigenic structures and waning humoral immunity to SARS-CoV-2 are harbingers of a long pandemic. Administration of a third dose of an inactivated virus vaccine can boost the immune response. Here, we have dissected the immunogenic profiles of antibodies from 3-dose vaccinees, 2-dose vaccinees and convalescents. Better neutralization breadth to VOCs, expeditious recall and long-lasting humoral response bolster 3-dose vaccinees in warding off COVID-19. Analysis of 171 complex structures of SARS-CoV-2 neutralizing antibodies identified structure-activity correlates, revealing ultrapotent, VOCs-refractory and broad-spectrum antigenic patches. Construction of immunogenic and mutational heat maps revealed a direct relationship between "hot" immunogenic sites and areas with high mutation frequencies. Ongoing antibody somatic mutation, memory B cell clonal turnover and antibody composition changes in B cell repertoire driven by prolonged and repeated antigen stimulation confer development of monoclonal antibodies with enhanced neutralizing potency and breadth. Our findings rationalize the use of 3-dose immunization regimens for inactivated vaccines. of 1: 10, with ~14% (3/22) and 16% (2/12) showing a near ineffectiveness in 122 neutralizing B.1.351 in vitro (Fig. 1A) . By contrast, only 1 out of 14 samples from 123 the 3-dose vaccinees exhibited a weak neutralizing titer below 10 (Fig. 1A) . 124 Importantly, the 3-dose vaccinees showed over 2.5-fold higher neutralizing potency 125 against B.1.617.2 than the convalescents and 2-dose vaccinees (Fig. 1A) . The GMT VOCs with minimal decreasing folds than those of 2-dose vaccination and 157 convalescents ( Fig. 1D and fig. S2 ). Fig. 1G and H) . Remarkably, NAb titer surged by ~8-fold (from 7 to 53) 175 at week 1, peaked by ~25-fold increase (up to 177) at week 2 after the 3 rd -booster 176 and slowly decreased over time (Fig. 1G) . Notably, NAb titer was maintained at 177 around 60 on 180 days post the 3 rd -booster, comparable to the high level of NAb titer 178 elicited by the 2-dose administration (Fig. 1H ). Taken together, these serological 179 results reveal a third-dose booster can elicit an expeditious, robust and long-lasting The molecular mechanism underlying these potent, broad and durative antibody 183 . CC-BY 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 5, 2021. Fig. 2A and fig. S3 ). The averaged percentage of S-binding memory B 192 cells in 3-dose vaccinees was substantially greater than those in 2-dose vaccinees 193 ( Fig. 2A and fig. S3 ). Due to differences in labeling strategies employed for sorting is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 5, 2021. ; https://doi.org/10.1101/2021.09.02.21261735 doi: medRxiv preprint repeated exposures of antigen. Among these antibodies tested, 26 bound to RBD, 16 246 targeted NTD, and 6 interacted with neither RBD nor NTD, but bound S1 (S1/non-247 RBD-NTD) ( fig. S9 and table S1). Pseudovirus neutralization assay revealed that all 248 RBD-specific antibodies, 10 (~60%) of the 16 NTD-directed antibodies and 3 249 (~50%) of the 6 S1/non-RBD-NTD antibodies were neutralizing, presenting a 250 relatively high ratio for NAbs (Fig. 2F, fig. S10 and table S2). Authentic SARS-CoV- is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint of the class III antibodies is presumably mediated by L452R (Fig. 3E) . Class II 322 antibodies use more diverse VH-genes and target the patch lying between sites I and 323 III ( Fig. 3D and fig. S19) . Surprisingly, antibodies binding to site II possess relatively 324 lower specificity in recognition of epitope clusters ranging from K417, L452, S477, is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 5, 2021. ; https://doi.org/10.1101/2021.09.02.21261735 doi: medRxiv preprint VOCs ( Fig. 3C and fig. S16 ). Related to the binding position, site IV epitopes, 339 accessible in both "open" and "closed" conformations, exist either as partially 340 overlapped with or outside ACE2 binding sites (Fig. 3A) . Interestingly, class IV is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 5, 2021. ; https://doi.org/10.1101/2021.09.02.21261735 doi: medRxiv preprint using the 171 NAb complex structures to estimate in vivo NAb-targeting frequencies 370 on the RBD and viral mutation frequencies (calculated from the datasets in the 371 GISAID), respectively ( Fig. 3D and fig. S19 ). Briefly, for each antibody, we 372 identified epitope residues and calculated the frequency of each RBD residue being 373 recognized by antibody. Immunogenic heatmap revealed that the epitope residues of 374 sites I to III showed predominantly higher NAb recognition frequencies (about 53.8, residues on average for site IV, V and VI, respectively), suggesting that class I to III 378 antibody epitopes are "hot" immunogenic sites ( Fig. 3D and fig. S19 ). In line with 379 this, residues within sites I to III exhibited dramatically higher mutation frequencies, 380 as revealed in circulating variants that include mutations of K417, L452, S477, T478, 381 E484 and N501 residues ( Fig. 3D and fig. S19) . Surprisingly, none of the top 9 hottest 382 immunogenic residues had a high mutation frequency. In particular, residues, such is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 5, 2021. ; https://doi.org/10.1101/2021.09.02.21261735 doi: medRxiv preprint IV to VI was reported possibly due to their less potent activities at the early time is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 5, 2021. Colored slices reveal clones that share the same IGHV and IGLV genes. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 5, 2021. ; Estimated transmissibility and impact of SARS-CoV-2 lineage 672 B.1.1.7 in England mRNA vaccine-elicited antibodies to SARS-CoV-2 and 675 circulating variants. nature Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus 677 by BNT162b2 vaccine-elicited human sera Multiple SARS-CoV-2 variants escape neutralization 680 by vaccine-induced humoral immunity Resurgence of COVID-19 in Manaus, Brazil, despite high 686 seroprevalence Dynamics of SARS-CoV-2 neutralising antibody responses and 689 duration of immunity: a longitudinal study Durability of Responses after SARS-CoV-2 mRNA-1273 Safety, tolerability, and immunogenicity of an inactivated SARS-695 CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-696 controlled, phase 1/2 clinical trial Development of an inactivated vaccine candidate for SARS-CoV-2 Measuring immunity to SARS-CoV-2 infection: 701 comparing assays and animal models Comparison of Four SARS-CoV-2 Neutralization Assays. 704 Vaccines 9 Immunogenicity and safety of a third dose, and immune 706 persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from 707 a double-blind, randomized, placebo-controlled phase 2 clinical trial. medRxiv Naturally enhanced neutralizing breadth against SARS-CoV-710 2 one year after infection Development of potency, breadth and resilience to viral 713 escape mutations in SARS-CoV-2 neutralizing antibodies. bioRxiv, (2021) Evolution of antibody immunity to SARS-CoV-2 Enhancement versus neutralization by SARS-CoV-2 antibodies from 718 a convalescent donor associates with distinct epitopes on the RBD Structure, Function, and Antigenicity of the SARS-CoV Cryo-EM structure of the 2019-nCoV spike in the prefusion 727 conformation Structural basis for bivalent binding and inhibition of SARS-CoV-2 730 infection by human potent neutralizing antibodies The antigenic anatomy of SARS-CoV-2 receptor binding 733 domain Structural basis of a shared antibody response to SARS-CoV-2 A SARS-CoV-2 neutralizing antibody selected from COVID-738 19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD 739 mutations Molecular basis for a germline-biased neutralizing antibody 742 response to SARS-CoV-2. bioRxiv, (2020) Paired heavy and light chain signatures contribute to potent 745 SARS-CoV-2 neutralization in public antibody responses. bioRxiv, (2021) The neutralizing antibody, LY-CoV555, protects 748 against SARS-CoV-2 infection in nonhuman primates A SARS-CoV-2 neutralizing antibody with extensive Spike binding 751 coverage and modified for optimal therapeutic outcomes Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy Antibody evasion by the P.1 strain of SARS-CoV-2 SARS-CoV-2 neutralizing antibody structures inform 759 therapeutic strategies An Alternative Binding Mode of IGHV3-53 Antibodies to the 762 SARS-CoV-2 Receptor Binding Domain Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally 765 Structural basis for potent neutralization of SARS-CoV-2 768 and role of antibody affinity maturation A noncompeting pair of human neutralizing antibodies block 771 COVID-19 virus binding to its receptor ACE2 A human neutralizing antibody targets the receptor-binding site of 774 SARS-CoV-2 Antibody neutralization of SARS-CoV-2 through ACE2 receptor 777 mimicry Structures of Human Antibodies Bound to SARS-CoV Spike Reveal Common Epitopes and Recurrent Features of Antibodies Rational development of a human antibody cocktail that deploys 783 multiple functions to confer Pan-SARS-CoVs protection Structure-based development of human antibody cocktails against 786 SARS-CoV-2 Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced 789 Potency and Resistance to Escape Mutations Bi-paratopic and multivalent VH domains block ACE2 binding 792 and neutralize SARS-CoV-2 Development and structural basis of a two-MAb cocktail for 795 treating SARS-CoV-2 infections Mapping Neutralizing and Immunodominant Sites on the SARS-798 CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology Studies in humanized mice and convalescent humans yield a 801 SARS-CoV-2 antibody cocktail A Therapeutic Non-self-reactive SARS-CoV-2 Antibody 804 Protects from Lung Pathology in a COVID-19 Hamster Model Potent SARS-CoV-2 binding and neutralization through 807 maturation of iconic SARS-CoV-1 antibodies Ultrapotent human antibodies protect against SARS-810 CoV-2 challenge via multiple mechanisms Multivalency transforms SARS-CoV-2 antibodies into 813 ultrapotent neutralizers Synthetic nanobody-SARS-CoV-2 receptor-binding domain 816 structures identify distinct epitopes. bioRxiv An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by 819 stabilizing inactive Spike Modular basis for potent SARS-CoV-2 neutralization by a 822 prevalent VH1-2-derived antibody class A therapeutic neutralizing antibody targeting receptor binding 825 domain of SARS-CoV-2 spike protein In vitro and in vivo functions of SARS-CoV-2 infection-enhancing 828 and neutralizing antibodies An alpaca nanobody neutralizes SARS-CoV-2 by blocking 831 receptor interaction Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block 834 interaction with ACE2 Human neutralizing antibodies elicited by SARS-CoV-2 infection Potent Neutralizing Antibodies against SARS-CoV-2 Identified by 839 Single-Cell Sequencing of Convalescent Patients' B Cells Potent neutralizing antibodies against multiple epitopes on 842 SARS-CoV-2 spike Structure-guided multivalent nanobodies block SARS-CoV-2 845 infection and suppress mutational escape Versatile and multivalent nanobodies efficiently neutralize 848 SARS-CoV-2 Double lock of a potent human therapeutic monoclonal antibody 851 against SARS-CoV-2 Structural basis for accommodation of emerging B.1.351 and 854 B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies. Structure Selection, biophysical and structural analysis of synthetic 857 nanobodies that effectively neutralize SARS-CoV-2 B cell genomics behind cross-neutralization of SARS-CoV-860 2 variants and SARS-CoV A combination of cross-neutralizing antibodies synergizes to 863 prevent SARS-CoV-2 and SARS-CoV pseudovirus infection Cross-neutralization of SARS-CoV-2 by a human monoclonal 866 SARS-CoV antibody Antibodies to the SARS-CoV-2 receptor-binding 869 domain that maximize breadth and resistance to viral escape. bioRxiv Structural basis for the neutralization of SARS-871 CoV-2 by an antibody from a convalescent patient A highly conserved cryptic epitope in the receptor binding 874 domains of SARS-CoV-2 and SARS-CoV Structural basis for neutralization of SARS-CoV-2 and SARS-CoV 877 by a potent therapeutic antibody Humoral immune response to circulating SARS-CoV-2 variants 880 elicited by inactivated and RBD-subunit vaccines Structure-based development of three-and four-antibody cocktails 883 against SARS-CoV-2 via multiple mechanisms Cryo-electron microscopy structures of the N501Y SARS-CoV-2 886 spike protein in complex with ACE2 and 2 potent neutralizing antibodies Structural insight into SARS-CoV-2 neutralizing antibodies 889 and modulation of syncytia Diverse immunoglobulin gene usage and convergent epitope 892 targeting in neutralizing antibody responses to SARS-CoV-2 Isolation and characterization of cross-neutralizing 895 coronavirus antibodies from COVID-19+ subjects SARS-CoV-2 RBD antibodies that maximize breadth 898 and resistance to escape Structural insights into the cross-neutralization of SARS-CoV 900 and SARS-CoV-2 by the human monoclonal antibody 47D11 LY-CoV1404 potently neutralizes SARS-CoV-2 variants Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and 905 convalescent serum Ultrapotent antibodies against diverse and highly transmissible 908 SARS-CoV-2 variants A proof of concept for neutralizing antibody-guided vaccine design 911 against SARS-CoV-2 Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike N-terminal domain antigenic mapping reveals a site of 916 vulnerability for SARS-CoV-2 Potent SARS-CoV-2 neutralizing antibodies directed against spike 919 N-terminal domain target a single supersite A neutralizing human antibody binds to the N-terminal domain 922 of the Spike protein of SARS-CoV-2 Prevalent, protective, and convergent IgG recognition of 925 SARS-CoV-2 non-RBD spike epitopes SARS-CoV-2 can recruit a heme metabolite to evade antibody 928 immunity An infectivity-enhancing site on the SARS-CoV-2 spike protein 931 targeted by antibodies Potent neutralizing antibodies from COVID-19 934 patients define multiple targets of vulnerability Therapeutic antibodies, targeting the SARS-CoV-2 spike 937 N-terminal domain, protect lethally infected K18-hACE2 mice Synthetic repertoires derived from convalescent COVID-19 940 patients enable discovery of SARS-CoV-2 neutralizing antibodies and a novel quaternary 941 binding modality. bioRxiv Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. 944 Effectiveness of Covid-19 Vaccines against the B.1.617.2 946 (Delta) Variant SARS-CoV-2 Delta VOC in Scotland: demographics, risk 949 of hospital admission, and vaccine effectiveness Analysis of SARS-CoV-2 variant mutations reveals neutralization 952 escape mechanisms and the ability to use ACE2 receptors from additional species Structures of SARS-CoV-2 B.1.351 neutralizing antibodies 956 provide insights into cocktail design against concerning variants Structural and functional ramifications of antigenic drift in recent 959 SARS-CoV-2 variants Resistance of SARS-CoV-2 variants to neutralization by 962 monoclonal and serum-derived polyclonal antibodies Therapeutic effect of CT-P59 against SARS-CoV-2 South African 965 variant Increased resistance of SARS-CoV-2 variant P.1 to antibody 968 neutralization Evidence of escape of SARS-CoV-2 variant B.1.351 from 971 natural and vaccine-induced sera A broadly neutralizing antibody protects against SARS-980 pre-emergent bat CoVs, and SARS-CoV-2 variants in mice. bioRxiv Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-983 elicited antibodies In vivo monoclonal antibody efficacy against SARS-CoV-2 986 variant strains